Soldevilla et al. firstly identified high-affinity aptamers against CD40 and further conjugated CD40 agonist aptamer-shRNA chimera to target the inhibition of the Nonsense mRNA-Mediated Decay (NMD) to tumor cells. This evidence concerns the gene CD40 and neoplasm.